OSCRHealthcare · Healthcare PlansThe 11 Wall Street analysts covering Oscar Health, Inc. hold a median 12-month price target of $29 — -11.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 2 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Oscar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OSCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −11.6% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $20 → $27 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $35 → $39 |
| 7 Aug 2026 | UBS | Maintains | Neutral | $20 → $26 |
| 10 June 2026 | Barclays | Upgrade | Overweight | $30 → $35 |
| 10 June 2026 | Barclays | Upgrade | Overweight | — |
| 26 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | Baird | Maintains | Neutral | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 20 Apr 2026 | Jefferies | Upgrade | Hold | — |
| 9 Jan 2026 | UBS | Upgrade | Neutral | — |
| 5 Jan 2026 | Barclays | Upgrade | Equal-Weight | — |
| 11 Dec 2025 | Stephens & Co. | Initiates | Equal-Weight | — |
| 26 Nov 2025 | Piper Sandler | Upgrade | Overweight | — |
| 13 Nov 2025 | Wells Fargo | Maintains | Underweight | — |
| 10 Nov 2025 | Barclays | Maintains | Underweight | — |
| 7 Nov 2025 | UBS | Maintains | Sell | — |
| 14 Oct 2025 | Goldman Sachs | Initiates | Neutral | — |
| 7 Oct 2025 | Wells Fargo | Maintains | Underweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Oscar Health, Inc. returned +82.4% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 34% of US stocks
Cheaper than 79% of US stocks
Cheaper than 24% of US stocks
Cheaper than 57% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 60% of US stocks
Higher than 57% of US stocks
Higher than 89% of US stocks
Higher than 73% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oscar Health, Inc. has a market value of $9.2B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $15.3B. The latest quarter grew 70.4% year on year.
Net income over the same four quarters: $550.9M, a 3.6% net margin.
Diluted earnings per share, trailing twelve months: $1.40.
Free cash flow in the twelve months to 30 June 2026: $4.4B.
Trailing P/E: 22.9×; forward P/E: 15.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Oscar Health, Inc. employs 2,305 people — $6.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oscar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Oscar Health reported a 46% jump in membership to 2.96 million. However, seasonal enrollment patterns and medical utilization keep profitability concerns in focus for the company.
Why it matters — OSCR watchers would care because strong membership growth is tempered by ongoing questions about whether profitability can be maintained given seasonal enrollment and medical utilization trends.
Oscar Health, Inc. (OSCR) was included on the Zacks Investment Research Rank #1 (Strong Buy) momentum stocks list for September 2, 2026, alongside LQDT and GEO.
Why it matters — An OSCR watcher would care because being added to a Zacks #1 (Strong Buy) momentum stock list signals favorable analyst ranking and momentum recognition for the stock.
Seeking Alpha highlights stocks with strong forward EPS growth as a way to diversify beyond AI infrastructure spending, citing healthcare payments and health insurance among attractive sectors. Oscar Health is noted as part of the consumer finance, healthcare payments, and health insurance group that may benefit from reduced reliance on the AI capex cycle.
Why it matters — The article positions health insurance companies like Oscar Health as attractive for investors seeking fundamental growth independent of AI infrastructure spending, which could increase attention on OSCR.
On September 2, 2026, Oscar Health, Inc. (OSCR) was added to the Zacks Rank #1 (Strong Buy) List, along with LCUT, CURI, CTOS, and CHYM. This designation was announced by Zacks Investment Research.
Why it matters — Oscar Health watchers would note that being added to the Zacks Strong Buy list signals a favorable analyst ranking for the stock.
Oscar Health's stock has risen 109% year-to-date, driven by strengthening membership, revenue and expansion plans, according to a Zacks Investment Research report. The piece notes the company's price-to-book multiple now tops the industry average.
Why it matters — OSCR watchers would care because the report highlights the insurer's strong operational growth and expansion momentum amid its elevated valuation relative to the industry.
The 11 Wall Street analysts covering Oscar Health, Inc. have a median 12-month price target of $29, with estimates ranging from $25 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Oscar Health, Inc., 3 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Oscar Health, Inc. 85 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Oscar Health, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies -11.6% from the last close, and Ticker Nerd's factor model ranks Oscar Health, Inc. 85 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Oscar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $39 over the next 12 months.
Oscar Health, Inc. returned +82.4% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States.
The most recent item we track (Zacks Investment Research, 2 Sept 2026): "Oscar Health Membership Surges but Profitability Remains Key". Oscar Health reported a 46% jump in membership to 2.96 million. However, seasonal enrollment patterns and medical utilization keep profitability concerns in focus for the company.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States. Oscar Health combines insurance coverage with a technology platform designed to help members access care, manage plans, and navigate the healthcare system. Its current offerings include individual and family health plans, small group coverage, and Medicare Advantage plans, along with technology solutions for providers and payors. The company operates in the managed health care and health services space, where it serves consumers and business customers through a data-driven, consumer-oriented model. Headquartered in New York, Oscar Health is positioned as a modern health insurer that integrates software, service, and clinical support across its insurance operations.
CEO Mr. Mark Thomas Bertolini · 2,305 employees · United States · https://www.hioscar.com
